Carao Ventures

Casdin Capital is a New York-based investment firm founded in 2012 by Eli Casdin, operating as a crossover fund that invests in life sciences and healthcare companies across both public and private markets, positioning itself at the intersection where deep scientific expertise and financial analysis meet. Eli Casdin brings backgrounds from Alliance Bernstein's thematic investment group and Bear Stearns to a conviction that the convergence of genomics, molecular biology, machine learning, and synthetic biology is creating the most significant investment opportunity in the history of healthcare. The firm invests in companies spanning biotechnology, diagnostics, digital health, oncology, genomics, and agtech, and takes positions across the full lifecycle from private venture rounds through publicly listed equities, applying a long-term fundamental approach. Casdin had approximately $2.2 billion in assets under management as of 2020, has made 265 investments, and has achieved 119 exits. The crossover model allows it to build relationships with companies at early private stages and maintain positions after IPO. Portfolio companies include 10x Genomics, the single-cell genomics instrument company; Absci, the AI-powered drug design company; Akeso, the biopharmaceutical company; BioNTech, the German mRNA therapeutics company that co-developed one of the leading COVID-19 vaccines; 23andMe; Adaptive Biotechnologies; Recursion Pharmaceuticals; and Ginkgo Bioworks. Beyond its original investments in 10x Genomics, Absci, Akeso, and BioNTech, the broader portfolio includes hundreds of life science companies across drug discovery, diagnostics, synthetic biology, and healthcare technology.